2 treatment settings, 0 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.
Every aggressive B-cell lymphoma biopsy is tested by fluorescence in situ hybridisation for MYC, and if MYC is rearranged, for BCL2 and BCL6. A lymphoma cannot be identified as double-hit by appearance, by immunohistochemistry for MYC and BCL2 protein, or by the cell-of-origin assay; dual protein expression is a separate and much commoner finding with its own, lesser, prognostic weight. Follicular lymphoma is excluded from the entity by both classifications even when it carries both rearrangements.
Histopathology examines tissue under a microscope. Immunohistochemistry uses antibodies to show selected antigens; both need specimen context and appropriate interpretation.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
Add these to your appointment list, or take the full question set for this cancer.
Often treated more intensively than diffuse large B-cell lymphoma, with prophylaxis against disease in the brain and spinal cord considered. The NCI summary says dose-intensive therapies, infusional therapies and stem cell transplant consolidation are being explored in this group. One randomised trial confined to double-hit lymphoma has reported, Alliance A051701 in 2026: adding venetoclax to dose-adjusted EPOCH-R did not lengthen progression-free survival and caused more deaths on treatment. No randomised trial has compared an intensified regimen with R-CHOP in this entity: the intensified regimens in use were adopted from retrospective comparisons after the group was shown to do less well with standard immunochemotherapy. The regimens, the doses and the evidence behind each are on the diffuse large B-cell lymphoma page and in the treatment layer of this family.
Rituximab was the first antibody ever approved for cancer (1997). It made chemoimmunotherapy the CLL standard for a decade, and biosimilars keep it cheap and everywhere.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Infusion-related reactions (first infusion) · US label, non-Hodgkin lymphoma studies; falls with each later infusion | 77% | - |
| Late-onset neutropenia (grade 3-4) · US label, previously untreated CLL on rituximab with fludarabine-cyclophosphamide, among 209 patients without prolonged neutropenia; 4.3% with fludarabine-cyclophosphamide alone | 14.8% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.